Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia Senti Bio today announced that patient dosing has commenced in the Phase 1 clinical trial of SENTI-202.

Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML) Senti Bio today announced the publication of preclinical data that supports the design of the Phase 1 clinical trial of SENTI-202.